Debiopharm announces results from Debio 0932 Phase I study on cancer

[News]

Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs and companion diagnostics, presented results of a Phase I open-label dose-escalation study with Debio 0932, an oral Heat Shock Protein 90 (HSP90) inhibitor in clinical development as an anti-cancer agent.

More... (http://www.news-medical.net/news/20120607/Debiopharm-announces-results-from-Debio-0932-Phase-I-study-on-cancer.aspx)